Evotec announces science chief exit and Evotec stock falls 3.93 percent

Evotec stock (ISIN DE0005664809) was trading at EUR 2.93 at Lang & Schwarz on October 2, 2026 at 4:40 p.m. CEST, down 3.93 percent versus the prior close of EUR 3.05. The company announced on September 29, 2026 that Chief Scientific Officer Cord Dohrmann would leave the role effective September 30, 2026.

Leadership change meets weak numbers

According to PR Newswire on September 29, 2026, Dohrmann stepped down by mutual agreement after serving as chief scientific officer and a management board member since 2010. Evotec said the search for a successor was ongoing, while management highlighted his work on iPSC-based technologies and omics capabilities.

The management change arrives alongside a difficult operating picture. Borse Express reported that second-quarter 2026 revenue reached EUR 143.50 million, down 16.00 percent from EUR 171.20 million a year earlier. First-half 2026 revenue totaled EUR 300.10 million, while adjusted EBITDA was negative EUR 42.70 million.

Guidance puts the turnaround on trial

Evotec's 2026 revenue guidance stands at EUR 570.00 million to EUR 610.00 million, below the previous EUR 700.00 million to EUR 780.00 million range. The same report placed adjusted EBITDA guidance between negative EUR 70.00 million and negative EUR 105.00 million, compared with the former range of EUR 0.00 million to EUR 40.00 million.

The cost program Horizon is intended to deliver annual savings of EUR 75.00 million by the end of 2027. That target is the key counterweight to the weaker revenue trend because it gives investors a measurable test for whether the restructuring can improve profitability.

Analyst target stays above the quote

Borse Express reported on September 26, 2026 that Berenberg kept its Hold rating and EUR 3.60 price target. The target lies 22.87 percent above the Lang & Schwarz price of EUR 2.93, calculated against the current euro quote.

The market is also approaching a defined information point. EQS News lists the third-quarter 2026 report for November 5, 2026. The next report will show whether revenue stabilization and Horizon savings are beginning to offset the guidance cuts.

Evotec stock tests investor confidence

Evotec's price sits EUR 4.77 below the 52-week high of EUR 7.70 and EUR 0.20 above the 52-week low of EUR 2.73, based on the October 2, 2026 market quote. The combination of a 16.00 percent second-quarter revenue decline, negative adjusted EBITDA and a EUR 3.60 analyst target leaves the November report as the clearest near-term test of the turnaround.

The further course of trading is shown by the continuously updated real-time quote of Evotec stock.

More news and analyses on Evotec stock